Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.

http://www.wikidata.org/entity/Q36758024

about

Charting the molecular network of the drug target Bcr-Abl Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo.Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.Cotargeting survival signaling pathways in cancer.MiRNA182 regulates percentage of myeloid and erythroid cells in chronic myeloid leukemia.Role of gene-expression profiling in chronic myeloid leukemia.Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors.BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention.Gambogic acid induces death of K562 cells through autophagy and apoptosis mechanisms.NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.Cell biology: a key driver of therapeutic innovation.Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.First annual report of the Austrian CML registry.Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.Leukemic cells with increased telomerase activity exhibit resistance to imatinib.A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia.Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.

P2860

Q24317707-96468763-9BE6-4DB5-B7ED-F7780B4AFB81 Q26768158-0C09E1A5-D0C0-4EB4-8554-4B79EFD7DAD7 Q34521001-E0A5272E-3CB6-4F7A-B4DB-97D5B4B55693 Q36088198-F1BF6C0A-BB11-40A9-82C8-50F8FB5040DA Q36478440-8E49E953-BD74-4987-A162-AFEBD2317FA8 Q36697774-6BBA7B33-67CD-49EC-AEBE-8DE656FCAC15 Q36857570-C91638C4-B2F0-4674-875A-B7E4EBE5F634 Q37170788-46C6A760-9FB4-4365-B530-11219167B0AE Q37251728-A749982B-1309-479C-95AE-04338E9509F7 Q37744933-385CA354-CC90-46F1-800E-3D78C9B3AF86 Q37810111-1CC3165B-4EAE-415C-9524-1BCAEE153FF8 Q37830694-D2BC2145-83A8-464C-BE54-C88A2FC90A2E Q37836928-EBC77175-5D29-4BD9-806C-93ACDB233F31 Q38907835-30CEFD9D-C5CF-430B-B3AC-7349D51035D0 Q39122858-37C37E4B-B282-4E09-8389-46941336A4AA Q41265920-382A69C5-2B81-4BBD-A4A5-27E1956A6BB3 Q41807279-77C2BA7E-1EDD-4118-89B8-617E4A5072BD Q42862831-DEDB8299-F98D-45AE-9181-EB52ACEAB4E6 Q43078241-23791CE1-7EDC-4134-92ED-97757F4012AA Q46527302-80D03E0B-A1E4-4459-BB22-07F1D1B1067A Q46854633-46E79036-9A7D-45FA-9AED-5FE253630839 Q53197147-6098804B-820F-47B1-8AAC-6696ACC1372F

P2860

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.

http://www.wikidata.org/entity/Q36758024

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.

@ast

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.

@en

type

label

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.

@ast

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.

@en

prefLabel

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.

@ast

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.

@en

P1433

Q36758024-5267AB4E-F739-4600-B00E-E0C71402A097

P1476

Q36758024-C4C74900-3B01-4536-844C-085F3E378DCC

P2093

Q36758024-0DF939ED-6AC2-43FB-A785-3B1DE62C9BF5

P2860

Q36758024-09483CDF-6392-458E-8D3B-E025900F51D6

Q36758024-0985B989-7FC3-4141-93B9-D0A28DC79E8D

Q36758024-103C69F4-F905-4671-8443-7D67F3E40C72

Q36758024-2525E280-975F-4D71-89EB-C441B8D9C8A4

Q36758024-296F3687-9E5A-46BA-914A-F1B576D34841

Q36758024-3621E6B6-4B0D-47E5-BE34-3CB7E7F41226

Q36758024-369694BC-9230-4ABA-AF9F-66C4835124B3

Q36758024-371B6C3B-446A-4C13-9ED2-A90B9B93CFBF

Q36758024-3A6352B4-227C-45C6-91CA-67562E5A88A8

Q36758024-40985C65-A85E-4165-8FCA-AB51CB750018

P304

Q36758024-B2F2946D-CF48-495E-A64C-FBBCF9F4C87F

P31

Q36758024-1AAA36FD-070A-4872-932A-49C350A8ACF5

Q36758024-3D762390-349C-4C8F-B4FE-E7C9C6EAEF1A

Q36758024-fd3475c1-2613-475a-a438-9b3e770e8b38

P356

Q36758024-935E4CA6-11E5-4F7B-B706-10118972B3E0

P407

Q36758024-FE7C3426-4F9B-40C5-8D85-02F83829F1D0

P433

Q36758024-D4EE4A8E-EB15-46B0-962F-CC515CBBD0F5

P478

Q36758024-8813453E-40B2-4E08-AD81-2318999F01D0

P577

Q36758024-6CA054E6-FA53-41B7-B60C-57440D7FECDA

Q36758024-8EDF99A9-0C00-4770-A614-829FDF4AD48C

P5875

Q36758024-0181E688-5ADA-4A1A-BD49-A00F1D0493C9

P698

Q36758024-80436FB5-C17B-4F14-A3A9-5EAA24F253E6

P921

Q36758024-6356EF3D-6766-49FF-838F-7284F7A00751

Q36758024-999E9372-B635-4E52-A4E7-7A789E00043B

P932

Q36758024-F3A83348-9811-4211-B74E-C696D7B6C6A8

P356

P1433

Journal of Experimental Medicine

P1476

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.

@en

P2093

Richard A Van Etten

http://www.w3.org/2001/XMLSchema#string

P2860

Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Overriding imatinib resistance with a novel ABL kinase inhibitor

Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis

Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5.

Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.

Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.

P304

461-465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20062335

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

204

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2007-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6454460

http://www.w3.org/2001/XMLSchema#string

P698

17353369

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

2137897

http://www.w3.org/2001/XMLSchema#string